Peer-reviewed veterinary case report
Iridium-192 interstitial brachytherapy as adjunctive treatment for canine cutaneous mast cell tumors.
- Journal:
- Journal of the American Animal Hospital Association
- Year:
- 2004
- Authors:
- Northrup, Nicole C et al.
- Affiliation:
- Department of Small Animal Medicine and Surgery · United States
- Species:
- dog
Abstract
Eleven dogs with cutaneous mast cell tumors (MCTs) were treated with surgery and iridium-192 ((192)Ir) interstitial brachytherapy. Minimum tumor doses ranged from 47.2 to 63.3 Gy. Treated tumors were classified as grade II (n=7) or III (n=4). Five dogs had recurrences with a median progression-free interval of 1391 days, and six dogs had no recurrence at a median follow-up time of 942 days. Acute adverse effects were well tolerated, and late effects were mild. One dog developed a second tumor of a different cell type in the radiation treatment field.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication: https://pubmed.ncbi.nlm.nih.gov/15238561/